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Abstract
Acute leukemia comprises of 31% of all cancers in children making it the most com‐
mon childhood malignancy. Significant strides have been made in treatment, partly
through risk stratification and intensified therapy. A number of subtypes remain at
high risk for relapse and poor outcome, despite current therapies. Here we describe
risk stratification and molecular diagnosis used to identify high risk leukemias and
guide treatment. Specific cytogenetic alterations that contribute to high risk B and T
cell acute lymphoblastic leukemia (ALL), as well as infant leukemia are discussed.
Particular attention is given to genetic alterations in IKZF1, CRLF2, and JAK, that
have been identified by whole genome sequencing and recently associated with Ph-
like ALL. Ongoing studies of disease mechanisms and challenges in developing
pre-clinical patient-derived xenograft models to evaluate therapies are discussed.
Keywords: Acute lymphoblastic leukemia, Pediatric Leukemia, high risk leukemia,
Ikaros, IKZF1, CRLF2
1. Introduction
Acute leukemia comprises 31% of all cancers in children, making it the most common child‐
hood malignancy. Acute lymphoblastic leukemia (ALL) makes up 80% of these cases and the
remaining are leukemias of the myeloid lineage. Among the lymphoblastic leukemias, there
are two immunophenotypic groups: B cell precursor ALL (B-ALL, 80% of all ALL) and T cell
ALL (T-ALL, 20%). In the following sections, the further classification of each of these subtypes
of leukemia, based on their molecular characteristics, is discussed. Also discussed are the
clinical importance, prognosis, and new therapies available for each subtype.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
2. Overview of classification of pediatric leukemia
2.1. Definition of standard and high risk leukemias
The National Cancer Institute (NCI) has classified acute lymphoblastic leukemia in children
based on age at diagnosis, initial white blood count, and the presence of extra medullary
disease.
• Standard risk: initial WBC count less than 50,000/μL and age 1 to younger than 10 years
• High risk: initial WBC count 50,000/μL or greater and/or age 10 years or older
The Children’s Oncology Group (COG) has classified acute leukemia into four risk groups
using prognostic factors that are strongly predictive of outcome such as: 1) age; 2) initial white
count; 3) gender; 4) presence of extra medullary disease at diagnosis (CNS or testicular disease);
and 5) blast cytogenetic findings and ploidy, and 6) response to induction therapy [1, 2].
Based on these factors, the four risk groups for COG classification of newly diagnosed B-ALL
for the AALL08B1 study are low risk, average risk, high risk, and very high risk. In T-ALL,
high white count does not have a prognostic significance. The above classification applies to
B cell phenotype cases. The presence of CNS or testicular disease, age <1 year, and trisomy 21
are considered high risk. The importance of tumor cell characteristics will be discussed in the
following sections.
2.2. Molecular diagnosis and its importance
Immunophenotyping is used to classify leukemia into B-ALL and T-ALL [3, 4].
B-ALL: comprises 80% of ALL. B-ALL cells express cytoplasmic CD79a, CD19, HLA-DR.
Surface CD10 (formerly known as common ALL antigen or CALLA) is seen in 90% of these
cases. Subtypes are as follows:
• Common Precursor B Cell ALL (75% of cases): These cells are CD10 positive and express no
surface or cytoplasmic Ig. This group has the best prognosis.
• Pro B ALL (5% of cases): Commonly seen in infants with MLL rearrangement. These cells
are CD10 negative and express no surface or cytoplasmic Ig.
• Pre B ALL (20% of cases): These cells express cytoplasmic Ig.
T-ALL: These cells express cytoplasmic CD3, with CD7 plus CD2 or CD5 on leukemic blasts.
T-ALL is associated with older age, male gender, high initial white count, and mediastinal
mass.
Cytogenetic alterations: The presence of recurrent numerical and structural chromosomal
abnormalities in both ALL and AML are very common and are associated with prognostic
significance. Hence, cytogenetic characteristics are now used for risk stratification of patients
with ALL [5, 6].
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Figure 1. Frequency of Cytogenetic Abnormalities in ALL
Table 1. Common Genetic Alterations and Clinical Significance B-ALL.
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Risk stratification based on cytogenetic characteristics has revealed many subgroups of NCI
standard and high risk groups that are now treated differently. Many treatment strategies
using targeted therapies directed at specific genetic alterations in the tumor cells have opened
up a new era of leukemia therapy. Figure 1 and Table 1 show cytogenetic abnormalities seen
in ALL [6, 7].
3. Infant leukemia and leukemia with MLL rearrangement
3.1. Overview of infant leukemia
Infant leukemia comprises only 1–2 % of childhood ALL. The cells often show an immature
pro-B phenotype. They present with very high WBC count and large extra medullary disease
burden which confer poor prognosis in this subset of children [8].
3.2. Biology of infant leukemia
Rearrangements of the KMT2A (also known as mixed lineage leukemia (MLL)) gene located
on chromosome 11q23 are seen in more than 80% of infant ALL, with increased frequency in
patients under 6 months of age. They are also seen in ~50% of infant AML [8] and a majority
of adults with therapy-related leukemia secondary to topoisomerase II inhibitors. Balanced
translocations result in the fusion of MLL to a number of different partner genes, leading to
the production of novel chimeric proteins with t(4;11)(q21;q23) MLL-AFF1 (also called MLL-
AF4) being the most common. Other rearrangements are t(11;19)(q23;p13.3) MLL-/ELN; t(6;11)
(q27;q23) MLL/MLLT4, also called MLL/AF6; t(9;11)(p22;q23) MLL/MFT3, also called MLL-AF9;
and t(10;11)(p12;q23) MLL/MLLT10, also called MLL/AF10. The MLL gene product plays a critical
role in hematopoiesis by regulating the HOX group of genes, which sequentially influence
hematopoietic stem cell renewal and leukemogenesis [9, 10].
3.3. Risk stratification, current therapeutic approaches and outcome in infant leukemia
Infant ALL is considered high risk for many reasons. The factors that confer poor prognosis
are age younger than 6 months, extreme hyperleukocytosis (>300,000 white blood cells/μL),
CD10 negativity, and the presence of MLL rearrangement. The type of the partner gene fused
to MLL does not seem to influence outcome [9, 11, 12]. Studies by the BFM group and the
international ALL protocol Interfant-99 have shown that patients who were early good
responders to prednisone therapy had a better outcome [13, 14].
Infant ALL is currently treated with intensive chemotherapy including high dose cytarabine
– “AML-like” therapy. The prednisone poor responders are classified as high risk and require
intensification of therapy. Hematopoietic stem cell transplantation for infants with ALL in first
remission remains controversial [15, 16].
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4. FLT3 mutations in ALL
4.1. Incidence of FLT3 alterations in ALL and its prognostic significance
Constitutive activation of FMS-like tyrosine kinase 3 (FLT3) plays an important role in the
pathogenesis of hematopoietic malignancies. FLT3 activating mutations, internal tandem
duplications (ITD), and kinase domain (KD) mutations were initially discovered in acute
myeloid leukemia (AML) and are associated with poor prognosis in both adult and pediatric
AML. However, in lymphoblastic leukemia, FLT3 ITD did not cause significant change in
overall survival and event free survival [17]. Recently, FLT3 overexpression has been seen in
two types of ALL: 18% of infant ALL with MLL rearrangement and 21–25% of hyperdiploid
ALL and in relapsed ALL samples [18, 19]. Studies have shown that high FLT3 expression
mutation identifies MLL-AF4+ (also called MLL-AFF1+) ALL patients at very high risk of
treatment failure and poor survival, emphasizing the value of ongoing/future clinical trials for
FLT3 inhibitors [20–23].
4.2. FLT3 inhibitors in the treatment of leukemia with FLT3 alterations
Recent gene expression studies have shown that in MLL-rearranged leukemia, FLT3, a receptor
tyrosine kinase that plays a role in promoting cell proliferation and transformation is overex‐
pressed. This has led to the pursuit of FLT3 inhibitors as targeted therapy for this disease [22].
Currently, Lestaurtinib (CEP-701™), an oral, highly selective small-molecule FLT3 inhibitor, is
being used in COG - phase III trial wherein infants with MLL-rearranged ALL are being
randomized to intensive chemotherapy with or without Lestaurtinib.
5. BCR-ABL positive leukemia
5.1. Incidence, current therapy, and outcome in BCR-ABL+ (Ph+) leukemia
Chimeric BCR–ABL1 protein is encoded by BCR-ABL1 fusion gene created by reciprocal t(9;22)
(q34;q11) translocation on chromosome 22, also known as the Philadelphia chromosome. The
BCR–ABL1 fusion gene is generated by joining most of the coding region of the ABL1 tyrosine
kinase gene (Abelson murine leukemia) on chromosome 9 to the breakpoint cluster region
(BCR) gene on chromosome 22. The molecular consequence of all BCR–ABL1 fusion proteins
is a hyperactive ABL1 kinase domain and aberrant phosphorylation of a variety of targets [23,
24]. There are two gene product variants: p190, which is seen in >90% of Philadelphia+ (Ph+)
ALL in children, and p210, which is seen in CML.
Ph+ ALL comprises 3–4% of pediatric ALL, and about 25% of adult ALL cases.  Prior to
tyrosine  kinase  inhibitors,  these  patients  had dismal  outcomes despite  the  use  of  inten‐
sive chemotherapy and hematopoietic stem cell  transplant in the first  remission was the
best available option [24].
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5.2. Tyrosine kinase inhibitors in BCR-ABL+ (Ph+) leukemia and current challenges
Imatinib was the first generation of tyrosine kinase inhibitors that changed the face of treatment
for Ph+ ALL and CML. The addition of Imatinib to intensive chemotherapy in childhood BCR-
ABL1–positive ALL results in a 4-year event-free survival rate of 84%, more than double that
of historical controls [25]. About 40% of the newly diagnosed Ph+ ALL patients carry point
mutations within the kinase-binding domain of BCR-ABL that confers resistance to Imatinib.
Dasatinib and Nilotinib are second-generation tyrosine kinase inhibitors. Dasatinib is a
multikinase inhibitor targeting several tyrosine kinases, including BCR-ABL and SRC kinases.
It is 325 times more potent than Imatinib, binds to the active and inactive forms of BCR-ABL,
and has excellent CNS penetration. These are effective in patients resistant to Imatinib, except
those with the T315I mutation [26].
Currently, allogeneic hematopoietic stem cell transplant (HSCT) is the standard of care in
second remission for patients with Ph+ ALL. It has been observed that most of the patients
treated with tyrosine kinase inhibitor (TKI)-based therapy will eventually relapse without
HSCT. However, benefits of allogeneic HSCT in first remission, after intensive chemotherapy
and TKI therapy, has to be considered based on donor availability, minimal residual disease
(MRD) status, and clinical status of the patient [27]. Recent studies in both adults and children
have failed to prove clear benefit of allogeneic HSCT in the first remission for this group of
patients mainly because of the small sample size [23, 28, 29].
6. Ikaros-altered ALL
6.1. Overview of Ikaros
Ikaros is a DNA-binding zinc finger protein encoded by the IKZF1 gene. Ikaros is a transcrip‐
tion factor that functions as a regulator of gene expression and chromatin remodeling [30].
Ikaros regulates the development and function of the immune system and acts as a master
regulator of hematopoietic differentiation. Genomic profiling studies identified IKZF1 as an
important tumor suppressor in ALL, particularly in ALL that is associated with poor prognosis
[31, 32]. The mechanism by which Ikaros suppresses malignant transformation and the
development of ALL is largely unknown. In the past few years, experiments by several groups
have shown that Ikaros regulates expression of its target genes by recruiting them to pericen‐
tromeric heterochromatin, resulting in their activation or repression [33, 34].
6.2. Clinical importance of Ikaros deletion
IKZF1 has been established as one of the most clinically relevant tumor suppressors in high-
risk ALL. Genome wide analysis studies have shown that 15% of all cases of pediatric B-cell
ALL show deletion of a single IKZF1 allele or mutation of a single copy of IKZF1, resulting in
haploinsufficiency of IKZF1. Haploinsufficiency occurs with expression of a functionally
inactive Ikaros splice form that acts as a dominant negative. Genetic inactivation of IKZF1 is
more rare in T-ALL where IKZF1 alterations occur in ~5% of cases [35]. Over 80% of BCR-ABL1
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ALL and 66% of chronic myeloid leukemia (CML) patients during lymphoid blast crisis show
mutation or deletion of an IKZF1 allele. One-third of BCR-ABL1 negative ALL patients also
show IKZF1 deletion or mutation. This group of patients is at increased risk of poor outcome
with more than threefold increase in relapse rate [30]. Poor outcome associated with IKZF1
alteration is frequently independent of age, sex, white cell count, and level of minimal residual
disease – factors which are commonly used for risk stratification. Testing for IKZF1 status at
the time of diagnosis is now being explored in prospective trials. In recent genome profiling
studies, IKZF1-altered high risk pediatric ALL cases have shown marked similarity to BCR-
ABL positive ALL giving rise to a new subset of cases now called “Ph-like “ or “BCR-ABL-
like” ALL. This will be discussed further later in the chapter.
6.3. Regulation of Ikaros function in T cell leukemia
The role of Ikaros in normal T cell development is demonstrated by evidence that Ikaros
regulates  the  expression  of  key  genes  in  T  cell  differentiation.  T  cell  differentiation  is
significantly  impaired  in  Ikaros-deficient  mice.  Terminal  deoxynucleotide  transferase
(DNTT) is a gene product critical for thymocyte differentiation that is regulated by Ikaros.
Ikaros also regulates the expression of CD4, CD8, and IL-2 and plays a critical role in T
cell differentiation [36, 37].
6.3.1. Regulation of Ikaros function
Casein kinase has been shown to phosphorylate Ikaros at multiple sites, and indeed, CK2
kinase is responsible for the majority of Ikaros phosphorylation. Studies by the Dovat group
showed that a single phosphomimetic mutation at amino acid 13 or 294 caused the redistrib‐
ution of Ikaros protein in the nucleus from pericentromeric localization to a diffuse nuclear
staining pattern, while phosphoresistant mutations produced no changes in the subcellular
localization of Ikaros. These data suggest that targeting of Ikaros to pericentromeric hetero‐
chromatin is regulated by its phosphorylation at specific amino acids [34, 38].
6.3.2. CK2 mediated phosphorylation of Ikaros impairs Ikaros function
Recent studies have demonstrated that CK2-mediated phosphorylation of Ikaros controls
essential functions of Ikaros including DNA-binding, subcellular localization, and chromatin
remodeling, as well as the level of Ikaros protein in cells (via ubiquitination and degradation).
Phosphorylation of Ikaros by CK2 kinase also regulates cell cycle progression and Ikaros
function in T cell differentiation [39, 40]. Since the overexpression of CK2 kinase and the loss
of Ikaros function have been strongly associated with leukemogenesis, it is proposed that
increased CK2 kinase activity leads to impaired function and/or degradation of Ikaros, which
results in malignant transformation and the development of leukemia.
6.4. Inhibition of CK2 as a potential therapeutic approach to treat high risk leukemia
Casein Kinase II inhibition has been an attractive therapeutic strategy in several malignancies.
A specific CK2 inhibitor, CX-4945, orally bioavailable small molecule is in Phase I clinical trial
for solid tumors. The role of CK2 inhibitor as an antileukemic drug in ALL needs to be explored.




7.1. Subclassification and treatment outcome of hypodiploid ALL
Hypodiploid ALL comprises 1–2% of all B-ALL cases and confers poor prognosis. Hypodi‐
ploid ALL is a chromosome number abnormality in the leukemic cells that results in 45
chromosomes or less. Hypodiploid ALL has been subdivided in various ways. In general,
Hypodiploid ALL may be subclassified into the following four groups:
• near-haploid cases – 24–31 chromosomes
• low-hypodiploid cases – 32–39 chromosomes
• high-hypodiploid cases – 40–43 chromosomes
• near-diploid cases – 44–45 chromosomes
Patients with 44 or 45 chromosomes have a much better outcome than patients with fewer than
44 chromosomes [41].
7.2. Genomic profiles of hypodiploid ALL
Recently, a large group of 124 pediatric patients with hypodiploid ALL were analyzed using
microarray profiling of gene-expression and copy-number alteration, and next-generation
sequencing. These analyses indicate that near-haploid and low-hypodiploid ALL are distinc‐
tive from each other and from other types of ALL. In near-haploid ALL, genetic alterations
target RTK (receptor tyrosine kinase) signaling, Ras signaling, and the lymphoid transcription
factor gene IKZF3, while in low-hypodiploid ALL, genetic alterations involve TP53, RB1,
and IKZF2 [42].
RTK and Ras signaling alterations were present in more than two-thirds (70.6%) of near-
haploid ALL cases, while they were much less common in low-hypodiploid (8.8%) and near-
diploid ALL (31.8%). The RTK and Ras signaling alterations involve deletion, amplification,
and/or sequence mutation of NF1, NRAS, KRAS, MAPK1, FLT3, or PTPN11.
The TP53 alterations were present in 91.2% of low-hypodiploid ALL, but less than 5% of non-
low-hypodiploid ALL. Meanwhile, TP53 alterations are also present in non-tumor cells in
43.3% of the mutation-carrying cases, suggesting that the TP53 mutations are inherited and
the low-hypodiploid ALL might be a manifestation of Li-Fraumeni Syndrome (LFS).
The Ikaros gene family is very important for lymphoid development and differentiation. IKZF2
is highly expressed in common lymphoid progenitors and pre-pro-B cells, while IKZF3 is
mainly expressed in more mature lymphoid precursors. IKZF2 and IKZF3 alterations occur in
low-hypodiploid and near-haploid ALL, respectively, suggesting that low-hypodiploid ALL
may arise from the transformation of a lymphoid progenitor that is a less mature lymphoid
than those from which near-haploid ALL arises. More importantly, both low-hypodiploid and
near-haploid leukemic cells show activation of Ras-signaling and PI3K-signaling pathways.
In addition, PI3K and mTOR inhibitors can inhibit proliferation of both low-hypodiploid and
Leukemias - Updates and New Insights8
near-haploid leukemic cells ex vivo, which indicates that these drugs should be further
investigated as a new therapeutic strategy for hypodiploid ALL [42].
8. Leukemias involving the E2A-PBX1 translocation
8.1. Introduction: Wild type E2A and PBX1
The TCF3 gene (also known as E2A) encodes two proteins, E12 and E47, which are generated
by differential splicing events. Both proteins contain a C-terminal basic helix-loop-helix
(bHLH) domain and two activation domains called AD1 and AD2. E2A proteins function as
transcriptional activators by binding to E-box DNA sequence and recruiting histone acetyl‐
transferase complexes. E2A proteins contribute to various aspects of lymphocyte differentia‐
tion and development. In E2A deficient mice, B cell development is arrested at the early pro-
B stage [43].
PBX1 was first described through its involvement in the translocation t(1; 19) [44]. PBX1 itself
is not expressed in lymphoid cells, though its related genes, PBX2 and PBX3, are expressed in
lymphocytes [45]. PBX1 contains a homeodomain involved in DNA binding and protein-
protein interaction. It can cooperate with other homeodomian containing proteins of HOX and
MEINOX classes to regulate the transcription of target genes [46].
8.2. Structure and function of the E2A-PBX1 translocation
The chromosomal translocation between chromosomes 1 and 19 results in a fusion event
between TCF3 and PBX1, which is detected in 3–5% of all pediatric pre-B cell ALL cases [47,
48]. The E2A-PBX1 fusion proteins contain two-thirds of the N-terminal of E2A proteins (which
retain the AD1 and AD2 domain, but lose the bHLH domain) and most of the PBX1 protein.
Two forms of E2A-PBX1 proteins are detected, E2A-PBX1a and E2A-PBX1b, which differ at
the C-terminus of PBX1 [49].
The E2A-PBX1 fusion protein is capable of transforming various cell types. Enforced expres‐
sion of E2A-PBX1 induces lethal lympho-proliferative diseases in transgenic mice and
aggressive myeloproliferative diseases in a murine bone marrow transplantation model [50].
8.3. Target genes of E2A-PBX1
Many efforts have been made to find the mechanisms by which E2A-PBX1 mediates transfor‐
mation of pre-B cells. One important way is try to find potential target genes or pathways that
are regulated by E2A-PBX1. Using ChIP-chip assay, Diakos et al. found 108 direct E2A-PBX1
targets [51]; however, few targets have been studied in detail. Wnt16 and EB-1 are two target
genes of E2A-PBX1 that are well studied. Wnt16 belongs to the Wnt family, a group of signaling
factors that plays important roles in many developmental processes including cell differen‐
tiation, proliferation, polarity, and migration [52]. Wnt16 is normally expressed in peripheral
lymphoid organs but not in bone marrow. In contrast, Wnt16 is highly expressed in bone
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marrow and cell lines that are derived from pre-B ALL patients carrying E2A-PBX1 [52]. EB-1
expression was much lower in marrow from pre-B ALL patients without t(1; 19) than marrow
from pre-B ALL patients and pre-B cell lines that contain the t(1; 19). EB-1 is a signaling protein
containing a phosphotyrosine binding domain, and may play a role in the regulation of cell
proliferation. [53].
8.4. Clinical treatment and outcome for E2A-PBX1 ALL
For pediatric B-ALL patients with the E2A-PBX1 fusion protein, the prognosis has been
controversial. It was initially associated with poor outcome when treated with antimetabolite-
based therapy [54, 55], but the recent development of intensified chemotherapy has much
improved the outcome of this subgroup. However, in a trial conducted by St. Jude Children’s
Research Hospital, although patients with the t(1; 19) had an overall favorable outcome with
intensified chemotherapy, this group had a significantly higher incidence of CNS relapse,
suggesting intensive CNS-directed therapy is needed to further improve the outcome in this
group of patients [56].
9. Ph-like ALL
9.1. Description and prevalence of Ph-like ALL
Ph-like (BCR-ABL1-like) ALL defines a distinct subtype of high risk ALL that is characterized
by a gene expression profile similar to that of Ph+ ALL but lacking the characteristic t(9;22)
translocation. This subtype represents about 15–20% of all cases of ALL [57, 58]. The prevalence
of Ph-like ALL increases with age: 10–13% of ALL in children and 21–27% of ALL in adolescents
and young adults. Patients with Ph-like ALL have higher leukocyte counts at presentation and
are more likely to have minimal residual disease at the end of induction chemotherapy. The
survival rates of patients with Ph-like ALL is significantly lower when compared to non-Ph-
like ALL among all age groups, adults faring worse than children [58]. Genes that are involved
in B cell development, including IKZF1 (Ikaros), are deleted more frequently in Ph-like ALL
as compared to non-Ph-like ALL (82% vs. 36%) [57, 58]. Genomic alterations involving kinase
signaling have been observed in >90% of Ph-like ALL. These include alterations involving
ABL1, JAK, EPOR, CRLF2, IL7R, FLT3, Ras, and others [58]. Subtypes of Ph-like ALL are shown
in Figure 2.
9.2. Translocations involving ABL1 in Ph-like B-ALL
The BCR-ABL1 translocation and the resulting Ph+ leukemia was described in Section 4. Other
translocations involving the ABL1 gene have been demonstrated in B-ALL as well as T-ALL.
The ETV6 gene encodes an Ets family transcription factor that is essential for hematopoiesis
and vascular growth. The ETV6-ABL1 fusion, t(9;12)(q34;p13) is a rare event that has been
reported in 22 cases of hematological malignancies including 6 cases of B-ALL and one case
of T-ALL [59]. The RCSD1-ABL1 fusion, t(1;9)(q24;q34), has been identified in 3 cases of B-ALL
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[60]. One case of B-ALL with SFPQ-ABL1 fusion, t(1;9)(p34;q34), and another case of B-ALL
with ZMIZ1-ABL1 fusion, t(9;10)(q34;q22.3) have been reported [61, 62].
Figure 2. Ph-like ALL subtypes
The NUP214 gene encodes a nuclear pore complex protein that is involved in nucleocytoplas‐
mic transport. NUP214-ABL1 is the second most prevalent fusion gene involving ABL1. It has
been reported only in T cell ALL with a frequency of approximately 5%. So far, 60 cases of this
fusion have been reported in the literature involving both childhood and adult cases of T-ALL
[63, 64]. In one study by Graux et al., extrachromosomal (episomal) amplification of ABL1
within the NUP214-ABL1 transcript was observed in 5 out of 90 cases of T-ALL. Episomes are
extrachromosomal DNA that are not visible by conventional cytogenetics [65]. The above
mentioned study utilized FISH and microarray-based comparative genomic hybridization
techniques to map the episomes and confirm the ABL1 amplification. Roberts et al. have
demonstrated that leukemias with ABL class fusions are sensitive in vitro to the ABL class
inhibitors Imatinib and Dasatinib [58].
9.3. Genetic alterations in Ph-like ALL that include EPOR and JAKs
A number of JAK mutations have been identified in Ph-like B-ALL, specifically mutations in
the JAK1 pseudokinase domain, as well as the JAK2 pseudokinase and kinase domain, and in
JAK3 [66]. However, the most common are those occurring in the JAK2 pseudokinase domain
– R683G [67]. Activating mutations in JAK kinases (JAK1, JAK2, and JAK3) have been reported
in approximately 10% of Ph-like pediatric ALL. The JAK mutations were associated with
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alterations in IKZF1 and CDKN2A/CDKN2B, and with poor outcomes [58, 67]. Approximately
50% of CRLF2 B-ALL patients show JAK mutations [66, 68, 69] while rearrangement or
translocations involving the JAK2 gene are characteristic of ~7% of Ph-like ALL [58].
Erythropoietin (EPO) is a hematopoietic growth factor for the erythroid lineage and regulates
the production of red blood cells. The binding of EPO to its receptor EPOR leads to downstream
activation of JAK2-STAT5, PI3 kinase, and MAP kinase pathways [70]. Rearrangements that
involve EPOR have been found in ~4% of Ph-like ALL [58].
9.4. Ras pathway genetic alterations in Ph-like ALL
Ras pathway mutations have been described in pediatric ALL cases. In a report from the
Children’s Oncology Group by Zhang et al., among 23 childhood B-ALL cases with a Ph-like
gene expression profile, 9% had Ras pathway mutations. However, the proportion of Ras
pathway mutated cases increased to 62% among ALL with focal ERG deletion [71]. Among
Ph-like B-ALL cases, 4% are known to have Ras pathway genetic alterations. A majority of
these involve missense mutations in KRAS and NRAS [58].
9.5. IKZF1 alterations in Ph-like ALL
Aberrations in the IKZF1 gene have been observed in 80% of pediatric B-ALL cases that harbor
the BCR-ABL rearrangement [72] and a similar pattern is seen in Ph-like ALL. Patients with
IKZF1 deletions have increased risk for relapse and poor treatment outcomes, making IKZF1
an independent predictor for treatment outcomes [73–75]. More recently, alterations of the
IKZF1 gene have been associated with other genetic defects including JAK mutations and
CRLF2 rearrangements. Mullighan et al. demonstrated that 70% of JAK mutated cases harbored
IKZF1 alterations [67]. Dorge et al. also performed a study which showed a higher number of
Ikaros deletions in patients that have P2RY8-CRLF2 rearrangement compared to those that are
negative for the rearrangement [73]. Further, in another study of 29 pediatric B-ALL cases that
showed high CRLF2 expression accompanied by CRLF2 rearrangement, ~70% of the patients
had JAK mutations and 80% of cases had deletions or mutations in IKZF1 [66]. These findings
provide evidence that CRLF2 rearrangements are significantly associated with alterations in
IKZF1, as well as JAK mutations. Moreover, in patients harboring CRLF2 rearrangements, JAK
mutations and IKZF1 deletions/mutations have a poor survival outcome, suggesting that these
three lesions cooperate to worsen prognosis and treatment outcome of high-risk B-ALL.
Therefore, they can serve as therapeutic targets, as well as prognostic tools that can be used
effectively in risk-stratification and treatment strategies to improve treatment outcomes in
CRLF2 and other high-risk B-ALL patients.
9.6. Rearrangement of CRLF2 in Ph-like ALL
Overexpression of CRLF2 is responsible for more cases of Ph-like ALL than any other genetic
alteration [58]. The CRLF2 gene is located in the pseudoautosomal region 1 (PAR1) of Xp/Yp.
Three types of CRLF2 gene alterations can result in overexpression of the CRLF2 protein on
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the surface of the leukemic cells. One involves the juxtaposition of Xp/Yp into the immuno‐
globulin heavy chain locus at 14q32 resulting in IgH-CRLF2 rearrangement. The other involves
a focal deletion of PAR1 that juxtaposes the regulatory elements of the purinergic receptor
gene P2RY8 to CRLF2 resulting in a chimeric fusion gene P2RY8-CRLF2. Thirdly, a less
common missense mutation in exon 6 of CRLF2, F232C, results in constitutive CRLF2 dimeri‐
zation [66, 76]. CRLF2 overexpression is present only in B-ALL cases without rearrangements
in ETV6 (TEL), KMT2A (MLL), TCF3, and BCR-ABL. It is also worth noting that more than half
of Down syndrome associated ALL overexpress CRLF2 resulting in poor outcomes in these
patients [69]. CRLF2 is overexpressed in approximately 8% of childhood and adult ALL and
comprises ~50% of Ph-like ALL [58].
10. Biology of CRLF2 B-ALL – The most common form of Ph-like ALL
10.1. CRLF2–TSLP cytokine receptor component in CRLF2 B-ALL
CRLF2 is a type I cytokine receptor that, along with the IL7 receptor alpha (IL-7Rα), forms a
heterodimeric receptor complex for the cytokine TSLP (thymic stromal lymphopoietin). In
normal B-cell progenitors the expression of CRLF2 is undetectable by flow cytometry, although
TSLP cytokine acts on these cells to induce proliferation [77]. In contrast, the high levels of
CRLF2 on CRLF2 B-ALL cells can easily be detected by flow cytometry [68]. In CRLF2 B-ALL
cells, TSLP has been shown to increase the phosphorylation of STAT5, AKT, and S6, indicating
increased JAK-STAT and AKT/mTOR signaling [78]. Studies of TSLP effects in a range of cell
types indicates that it can also indicate cell survival signals through the activation of several
biological pathways including ERK, MAPK, PI3K/AKT/mTORC1, and NFκB, at least in some
cell types [79]. The physiological significance of the signaling induced by TSLP in CRLF2 B-
ALL cells remains to be determined [78].
10.2. Role of JAK mutations in CRLF2 B-ALL
Overexpression of CRLF2 is believed to cooperate with other genetic lesions leading to
leukemogenesis and chemoresistance. In most patients, overexpression of CRLF2 and CRLF2
gene rearrangements has been associated with deletions and/or mutations of the IKZF1 gene.
Mutations in JAK1 or JAK2 are present in half of all cases of CRLF2-overexpressing B-ALL and
can result in constitutive activation of this pathway [66, 68, 69].
To understand the contributions of CRLF2 and JAK2 to leukemogenesis, several groups have
conducted studies using CRLF2 and JAK mutants. Results from cellular models that utilized
murine Ba/F3 cells transduced with combinations of patient-derived mutant JAK1 or JAK2,
and CRLF2 achieved cytokine-independent growth in cells that contained both CRLF2 and
JAK2 mutants. This cytokine independent growth did not occur in cells that were transduced
with wildtype CRLF2 alone or JAK2 mutants alone. Co-immunoprecipitation studies demon‐
strated that human CRLF2 and phosphorylated mutant JAK2 interact physically [76, 80]. These
research findings provide evidence that supports the hypothesis that CRLF2 and JAK2 can
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cooperate to produce leukemogenesis. Indeed, Hertzberg et al. showed that almost all patients
with JAK mutations harbor CRLF2 gene rearrangements[80] This is in keeping with CRLF2
serving as a scaffold to facilitate signaling of mutant JAK2 [81]. However, ~50% of CRLF2 B-
ALL patients show no JAK mutations, suggesting that another factor might be inducing JAK
activation. This is certainly consistent with the role of endogenous TSLP-induced CRLF2-
mediated JAK phosphorylation in CRLF2 B-ALL. TSLP has been shown to increase both JAK-
STAT and AKT/mTOR phosphorylation in human CRLF2 B-ALL cells – including those with
activating JAK mutations [78].
10.3. Inherited background variability and susceptibility to CRLF2 B-ALL
Aside from these acquired genetic variations that contribute to leukemogenesis, other studies
using Genome Wide Association techniques are employed to determine whether inherited
(germline) genetic variations increase susceptibility to the development of high-risk Ph-like
ALL. In a major study, 75 Ph-like ALL patients were compared to 6,661 non-ALL controls and
two Single Nucleotide Polymorphisms (SNPs) within the GATA3 gene achieved genome-wide
significance (rs3824662 and rs3781093). The results showed that both SNPs were over-
represented in Ph-like ALL and were associated with higher risk of relapse [82]. More
importantly, the GATA3 SNP (rs3824662) was associated with CRLF2 rearrangement, JAK
mutations, and IKZF1 deletions [82]. GATA3 is one of the six-membered GATA transcription
factor family that is involved in the reprogramming of somatic cells to pluripotency[83]. More
specifically, GATA3 is critical for T cell development [84] and genetic alterations in GATA3
have been observed in T-ALL patients [85] and in other hematopoietic disorders such as AML
and Hodgkin Lymphoma [86, 87]. Taken together, these studies provide evidence that in
addition to acquired genetic alterations such as CRLF2, inherited genetic variations such as
GATA3 SNPs may also contribute to increased susceptibility to developing CRLF2 B-ALL and
increased risk of relapse. Thus, germline and somatic genetic alterations may play an important
role in leukemogenesis.
10.4. CRLF2 B-ALL and health disparities
CRLF2 B-ALL is five times more prevalent in patients of Hispanic/Latino origin and after initial
treatment they experience a higher rate of relapse. This high prevalence of CRLF2 B-ALL in
Hispanics is further supported by studies that have been conducted in regions where there is
a high proportion of Hispanics. For example, the highest incidence of childhood ALL is in
Hispanics compared to other ethnic groups in California [88]. In a study of pediatric B-ALL
patients, 18 of 51 (35.3%) Hispanic/Latino patients harbored CRLF2 rearrangements compared
to 11 of 154 (7.1%) patients of other ethnicities [66]. Harvey et al. further demonstrated that in
addition to JAK mutations and IKZF1 deletions, CRLF2 rearrangement was also significantly
associated with Hispanic/Latino ethnicity [66]. It has been established that populations
originating from different ancestries can be distinguished by genetic polymorphisms that are
unique to their ancestors [89]. Therefore, the current approach to studying the mechanisms
that contribute to the racial disparities relating to incidence and outcome of ALL is to evaluate
ancestry-related genetic alterations in conjunction with external factors such as the environ‐
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ment and socioeconomic status [90, 91]. Recent studies to identify ALL susceptibility genes in
the Hispanic population demonstrated that ARID5B and GATA3 SNPs are more frequent in
Hispanics compared to other ethnicities [82, 92]. These SNPs have been associated with higher
ALL incidence (ALL susceptibility), increased frequency of relapse, and poorer outcome [82,
92]. A possible explanation for the increased frequency of these SNPs in Hispanics is their
shared genetic ancestry with Native Americans that also exhibit increased frequency of the
SNPs [92]. While ancestry-related studies can provide a basis for disease, there is still a need
for studies that will identify the biological factors that contribute to the health disparity. Thus,
there is a need for the development of preclinical animal models that can be used to evaluate
Hispanic patient samples, thereby allowing us to effectively study CRLF2 B-ALL in context of
racial disparities.
10.5. Challenges of preclinical models of CRLF2 B-ALL
Current strategies to treat Ph-like ALL and more specifically CRLF2 B-ALL include: 1)
stratification of patients using prognostic and clinical factors (age, gender, race, white blood
cell count, CNS involvement, testicular involvement, steroid pretreatment and MRD, cell
morphology, immunotyping and genetic alterations); and 2) administer treatment regimen
based on risk group. Since 91% of the Ph-like ALL subset of patients (including CRLF2 B-ALL)
is characterized by activated kinase signaling, tyrosine kinase inhibitors are currently recom‐
mended as part of the treatment regimen for these patients [58]. Recent studies were aimed at
evaluating the effects of tyrosine kinase inhibitors, more specially JAK inhibitors and PI3K/
mTOR inhibitors on CRLF2 B-ALL cells in vitro and in vivo [78, 93, 94]. Results from these
studies have shown that CRLF2 rearranged B-ALL cells are sensitive to these inhibitors in vitro
and in vivo. While JAK inhibitors and all other tyrosine kinase inhibitors have shown some
promise, they have not been effective in all Ph-like B-ALL and not all CRLF2 B-ALL harbor
JAK mutations. Since TSLP has been shown to increase activation of the JAK-STAT, PI3K/AKT/
mTOR signaling pathways, it is important to conduct studies of disease mechanisms and
evaluate therapeutic candidates in context of TSLP and other cytokines that are often present
in the cancer microenvironment. Though some in vitro studies were performed in the presence
of TSLP [78], in vivo studies in context of TSLP stimulation are lacking. Therefore systematic
evaluation of the contributions of TSLP to CRLF2 B-ALL leukemogenesis and the assessment
of therapies to treat these patients are required to gain a better understanding of the etiology
and treatment outcome of the disease.
Human-mouse xenograft models are ideal in vivo models for studying disease mechanisms
and for evaluating therapies for leukemia, particularly in context of inherited genetic varia‐
bility. NOD/SCID mice have been shown to be receptive to the engraftment of human leukemia
cells [95]. The development of additional mouse strains, such as the NOD/Scid/IL- 2Rγ null
(NSG) strain have significantly increased the ability of human ALL cells to engraft [96]. These
animal models are effective because mouse cytokines act on the human leukemia cells by
providing the necessary growth signals required to facilitate proliferation and maintenance of
leukemia cells [97]. However, while most mouse cytokines can activate receptors on human
cells, some mouse cytokines are species-specific, e.g., IL-3, GM-CSF, and TSLP [97]. This poses
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a challenge in effectively recapitulating the systemic or BM microenvironment present in
patients. It is important to conduct studies as far as possible with the full complement of
cytokines present under physiological conditions in order to truly identify disease mechanisms
and evaluate therapies.
10.6. Novel pre-clinical xenograft models that provide human cytokines
The  lack  of  cross  species  cytokine  activity  has  been  partially  addressed  for  studies  of
myeloid leukemia by the recent  development of  so-called “cytokine mice” [98].  These
immune-deficient mice express human IL-3,  SCF, and GMCSF, three cytokines that play
important roles in the production of myeloid lineage cells and show no or poor cross species
activity. Xenografts from cytokine mice showed enhanced AML engraftment [98]. Alterna‐
tive strategies have been used to produce mice that express human IL-15 and FLT3 and
other cytokines,  which have resulted in enhanced production of functional human natu‐
ral  killer  cells,  dendritic  cells,  monocytes/macrophages,  and erythrocytes  [97].  However,
human TSLP has not been included as part of the complement of cytokines used in these
studies.
Current xenografts that evaluate therapeutic candidates for CRLF2 B-ALL do not include
human TSLP [94], which is required to provide the human CRLF2-mediated signals that were
demonstrated by previous groups in vitro [78]. There is a need to develop new preclinical
animal models that include TSLP and other species-specific cytokines in order to accurately
evaluate disease mechanisms. A model that includes TSLP and allows for modulating the
levels of TSLP will be of great value to the study of CRLF2 B-ALL. The rationale for this is that
CRLF2, the receptor for the endogenous ligand TSLP, is overexpressed on CRLF2 B-ALL cells
and has contributed to increased pathway signaling in these cells. Additionally, the role of
TSLP in the initiation and maintenance of CRLF2 B-ALL is unknown. Current studies in our
laboratories are aimed at developing a human TSLP+ xenograft model that provides human
TSLP to activate CRLF2-mediated signals in human CRLF2 B-ALL cells transplanted into
xenograft mice. This model will be used to study disease mechanisms and identify therapies
to effectively treat CRLF2 B-ALL.
11. Conclusion
In summary, great strides have been made in effectively treating pediatric leukemia. Risk
stratification based on clinical features combined with intensified therapies has contributed to
this outcome. Increasingly, more precise molecular phenotyping available from whole genome
analyses make it possible to identify and study specific subtypes of high risk leukemias.
Mechanistic studies that identify druggable targets in aberrant pathways are likely to fuel rapid
advances in the future. This progress will depend on the development of relevant preclinical
models for studying disease mechanisms and for evaluating candidate therapies.
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